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Numerous studies have indicated that PPARγ plays multiple roles such as in inflammation, cell cycle control, cell proliferation,
apoptosis, and carcinogenesis, thus PPARγ contributes to the homeostasis. Many in vitro studies have showed that ligand-induced
activation of PPARγ possess antitumor effect in many cancers including CRC. However, the role of PPARγ in gastrointestinal
cancers, especially in colorectal cancer, is rather controversial. Nevertheless, some recent studies with the positive results on the
possible application of PPARγ ligands, such as Bezafibrate or Rosiglitazone in gastrointestinal cancers, have suggested a potential
usefulness of PPARγ agonists in cancer prevention and therapy. In this review, the authors discuss the recent developments in the
role of PPARγ in gastrointestinal cancers.
Copyright © 2009 Bing Zou et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. An Overview of PPAR Family
Peroxisome proliferator-activated receptor (PPAR) is a mem-
ber of a family of nuclear hormone receptors that consists
of three isoforms: PPARα, PPARγ, and PPARδ (also known
as PPARβ). Within this family are also retinoid X receptor
(RXR), vitamin D receptor, and the thyroid hormone recep-
tor. PPARs act as a ligand-activated transcription factor and
are involved in many different biological functions. Extensive
study of PPARs was probably sparkled by the identification
of PPARα in 1990 [1], which was soon followed by the
identification of two other members PPARγ and PPARδ [2,
3]. Each isoform of PPARs is encoded by a separate gene and
exhibits different tissue distribution patterns. For example,
PPARα is principally expressed in tissues that exhibit a high
rate of fatty acid metabolism (e.g., brown adipose tissue,
liver, kidney, and heart) and is the primary target for the
fibrate class of drugs [4]. PPARδ is ubiquitously expressed
in many tissues, and its physiological roles are multiple,
including but may not be limited to lipid trafficking [5, 6],
blastocyst implantation [7], wound healing [8], and the
regulation of fatty acid catabolism and energy homeostasis
[9, 10]. PPARγ is richly expressed in adipose tissue, intestinal
epithelial cells [11, 12], and macrophages. Low level of
PPARγ has also been found in skeletal muscle [13].
Like other nuclear receptors (NRs), all PPARs share a
similar modular structure with functionally distinct domains
called A/B (ligand-independent activation domain), C (DNA
binding domain), D (hinge domain), and E/F (ligand-
binding domain, LBD) (Owen et al. [14]). The N-terminal
domain A/B has been relatively well conserved through
evolution, whereas the C domain is the most conserved of
all the functional domains. The less conserved domain D
functions as a flexible hinge between the C and E/F domains
and contains a sequence recognized by transporting proteins.
Some of the amino acids are involved in the activities of
nearby domains, leading to the dimerization and recognition
of the target DNA sequences (Owen et al. [14]). The largest
domain is the LBD located at the C-terminus [15], which is
responsible for the binding of a specific ligand to PAR recep-
tors, and subsequent activation of PPAR through binding to
peroxisome proliferators response elements (PPREs) on the
promoter region of the target genes. Thus, LBD is the major
functionally related domain of the PPARs.
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PPARs seem to regulate gene transcription by two
mechanisms: transactivation and protein-protein interaction
with other transcription factors. Transactivation of PPARs is
a DNA-dependent mechanism, which involves binding of the
PPAR ligands and heterodimerization between PPARs and
RXR (Retinoid X receptor) [16]. The heterodimer between
PPARs and RXR then binds to PPRE, resulting in stimulation
of transcription. In contrast, the protein-protein interaction
mechanism involves the activation of target genes through
other transcription factors, such as AP1, NF-κB, Smads,
STATs, and NFATs. It is suggested that most of inhibitory
effects of PPARs are mediated by this mechanism [17,
18].
In this review, we only focus on the controversial role of
PPARγ human gastrointestinal cancers.
2. PPARγ
In human, the PPARγ gene is located on chromosome
3 at position 3p25.2 [19]. Two isoforms of PPARγ have
been identified: PPARγ1 and PPARγ2. These two isoforms
only differ in their N termini sequences: PPARγ2 protein
contains an additional 30 N-terminal amino acids, but is
otherwise identical to PPARγ1. Both PPARγ1 and PPARγ2
N termini function as translational initiators, but the activity
of PPARγ2 is higher than that of PPARγ1, suggesting
that PPARγ1 and PPARγ2 N termini have distinct activa-
tion capacities, and perhaps may have different functions.
PPARγ2 is predominantly expressed in adipose tissue, and
it has been demonstrated that PPARγ2 N termini is more
important in the process of adipocyte differentiation and
metabolism [20, 21]. In contrast, PPARγ1 is relatively stable
and expressed at very high levels in the gastrointestinal
epithelium [12, 22, 23], and low levels were observed inmany
other tissues [24].
The function of PPARγ relies on its interactions with a
coactivator or corepressor. Binding of PPARγ to a coacti-
vator affects the chromatin structure through acetylation of
histones, whereas binding of PPARγ to a corepressor alters
the chromatin structure through deacetylation of histones.
Both coactivators and corepressors are highly versatile and
are not specific for particular PPAR subtypes [25]. Binding
of PPARγ with coactivators may be either ligand-dependent
or ligand-independent. Most coactivators interact with the
LBD of NRs utilizing the LXXLL helical motifs in a ligand-
dependent manner [26, 27]. In contrast, PPARγ coactivator-
1α (PGC-1α) binds to the hinge domain of PPARγ in a
ligand-independent manner [28]. In addition to the ligand-
dependent and ligand-independent activation of PPARγ, the
activity of this transcription factor may also be modulated by
posttranscriptional modification, such as phosphorylation
[29–31].
3. PPARγ Ligands
Over the past several years, various natural and synthetic
PPARγ ligands have been identified, and new ligands are
under fast development.
In the broad sense, these ligands include specific PPARγ
agonists [32], PPARγ partial agonists [33], and PPARα/γ
dual agonists [34]. Synthetic PPARγ agonists are able to
modulate the adipocyte differentiation, and thus have been
used as potential antidiabetic drugs [20, 32, 33]. The most
commonly used PPARγ agonists are Thiazolidinediones
(TZDs), which include Troglitazone (Rezulin), Pioglitazone
(Actos), and Rosiglitazone (Avandia).
TZDs are widely used in animal studies and clinical
trials to investigate the role of PPARγ. The roles of PPARγ
ligands are multiple. Some TZDs have been licensed for use
in patients with Type 2 diabetes mellitus (T2DM) [35], some
may benefit cardiovascular parameters, such as lipids, blood
pressure, inflammatory biomarkers, endothelial function,
and fibrinolytic state [36, 37]. Moreover, they have been
successfully used in nondiabetic insulin-resistant conditions
such as polycystic ovary syndrome [38, 39]. The synthetic
PPARγ ligands, however, are associated with various side
effects, such as increased adiposity, edema, hepatotoxicity,
and cardiac hypertrophy. Therefore, partial PPARγ ligands
with weaker side effects such as LSN862 have been developed
[33, 40], and newer PPARγ ligands that do not fall into
the category of TZDs are under active development and
their biological activities have been tested in various cancer
cells. For example, the roles of LY293111 (Eli Lilly), CS-7017
(Sankyo), Spirolaxine (Sigma-Tau), and TZD-18 (Merck)
have been investigated in various in vitro systems, and some
are under clinical trials [41–45].
In addition to synthetic ligands, some endogenous
(or natural) compounds are potent activators for PPARγ.
Among the natural PPARγ ligands is cyclopentone 15-deoxy-
E12,14-prostaglandin J2 (15d-PGJ2). This agent is probably
the most potent endogenous PPARγ ligand [46, 47] and has
been widely used to study the role of PPARγ activation in
cancer cells [48].
4. Role of PPARγ in Tumorigenesis of
Gastrointestinal Cancers
As discussed earlier, PPARγ is richly expressed in the normal
gastrointestinal epithelium. Significantly high level of PPARγ
has been observed in the highly differentiated epithelial cells
of the proximal colon [11, 12] and small intestine [12, 49].
In small intestine, PPARγ is particularly expressed at the
crypt/villus junction where small intestine epithelial cells
cease to proliferate and undergo differentiation to mature to
functional villus epithelial cells. These observations indicate
that PPARγ might play an important role in the regulation
of differentiation of gastrointestinal epithelial cells. The fact
that PPARγ is expressed at a much higher level in the
proximal colon than in distal colon implies that PPARγ
may play a complex role in the colon. The mechanisms
by which PPARγ regulates the differentiation of human
gastrointestinal epithelial cells are not yet clear, but may
involve a collaboration of PPARγ with the transcription
factor Hic5 as the transactivation of Hic5 by PPARγ was
shown to promote differentiation of intestinal epithelial cells
during embryonic development [50].
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The expression pattern of PPARγ in colon cancer has
been previously reported. Loss-of-function mutations to
PPARγ have been reported to be associated with increased
propensity of human colon cancers [51] although the
mutation of PPARγ is very rare [52]. Many in vitro
studies have revealed that activation of PPARγ inhibits
proliferation and induces apoptosis of some colon cancer
cell lines [53–60]. Compatible with these findings, het-
eroxygous loss of PPARγ increases the susceptibility of
colon and stomach into carcinogen-induced colon cancer
and gastric cancer, respectively, [61–63]. Biallelic knockout
of PPARγ in colonic epithelial cells resulted in increased
tumor incidence and tumor size in APC+/Min mice [64], and
Pioglitazone suppressed colon tumor growth in APC+/Min
mice in a dose-dependent manner [65–67]. Similar results
were reported in studies conducted in other animal models.
Troglitazone inhibited the formation of preneoplastic colonic
aberrant crypt foci (ACF) in rats treated with either AOM
or the combination of AOM with dextran suflate (DSS)
[68, 69]. Several PPARγ ligands including pioglitazone,
rosiglitazone, and RS5444 have been reported to inhibit
ACF formation in AOM-mediated colon cancer models
[12, 67]. All these studies have suggested that PPARγ
functions as a tumor-suppressor gene and it might be
involved in cancer suppression under the physiological con-
ditions.
Carcinogenesis usually results from an imbalanced cell
proliferation and apoptosis. The inhibitory effect of PPARγ
activation on colon cancer could be attributed to sev-
eral mechanisms. For example, ligands-induced activation
of PPARγ was found to inhibit phosphatidylinositol 3-
kinase (PI3K)/Akt signaling and retinoblastoma protein
(Rb) dephosphorylation [70], induce expression of cyclin
D1 [71] and Bcl-xl/Bcl-2 [72], upregulate p21 and p27
[73–75], interact with XIAP [76], upregulate PTEN [77],
and enhance the sensitivity of tumor cells to tumor
necrosis factor-related apoptosis-inducing ligand- (TRAIL-)
induced cell death [78]. Inhibition of hyperlipidemia, a
well-established oncogenic factor for colon cancer, has also
been proposed as one of the mechanisms responsible for
the inhibitory effect of PPARγ ligand on colon cancer [65,
66].
Although induction of apoptosis by PPARγ agonists
has been frequently suggested as one of the mechanisms
responsible for their anticancer effects, it is less clear and
perhaps controversial whether PPARγ-induced apoptosis is
actually receptor-mediated, or apoptosis simply occurs as an
off target effect of PPARγ agonists.
To complicate the issues even further is the fact that
the inhibitory effect of PPARγ activation on colon cancer
formation does not have a universal support. For example,
two PPARγ agonists, troglitazone and rosigliatzone, have
been reported to promote gastrointestinal tumorigenesis
in C57BL/6J APCMin/+ mice [11, 79], raising the serious
concerns about the possibility that individuals who are on
TZDs for T2DM might be at risk for colon cancer. These
results were not able to be reproduced by other studies
[65, 66]. On the contrary, long-term treatment with high
concentrations of TZDs was found to increase the frequency
of caecal tumors in wild-type C57BL/6J and C57BL/6J
APC+/1638N/Mlh+/− double mutant mice [80]. Part of the
explanation is that in these mouse model studies, the doses
of TZDs used were far greater than the doses that can be
tolerated in human. Also, to add to the complexity of the
role of PPARγ in colon carcinogenesis, it has been reported
that many TZDs may activate PPARγ independent of PPARγ
receptor [72, 76, 81–84] but may require the presence of APC
gene [61].
The contradictory results reported in these studies have
clearly reflected the complexity of the role of PPARγ in colon
carcinogenesis. Large-scale in vivo studies using not only
PPARγ activators or inhibitors but also in knockout mice,
especially colon specific knockout of PPARγ, would generate
more valuable data.
5. Role of PPARγ during
Anti-Inflammatory Process
In recent years, the causative link between inflammation and
cancer has attracted considerable attention. The mechanism
and molecular pathways of chronic inflammation leading
to CRC development have been discussed in much detail
in a recent review [85]. It has been commonly agreed that
in the development of CRC, inflammatory bowel diseases
(IBD, which includes ulcerative colitis and Crohn’s disease)
are among the major risk factors. These risk factors are
particularly important in children and young adults of less
than 30 years of age [86, 87].
There is an ample amount of evidence suggesting a role
of PPARγ in inflammatory processes. PPARγ expression is
reduced in ulcerative colitis [88]. PPARγ has been identified
as anti-inflammatory molecules in IBD [89]. Mice with
a targeted disruption or elimination of the PPARγ gene
in intestinal epithelial cells showed an increased suscep-
tibility to dextran sulfate sodium- (DSS-) induced IBD
[90].
As macrophages play important role in the anti-
inflammatory effect in the colon, its correlation with PPARγ
has been actively studied. It has been shown that mice with
a targeted disruption of the PPARγ gene in the macrophages
of the intestinal epithelia also showed an increased suscepti-
bility to DSS-induced IBD [90, 91], suggesting an important
anti-inflammatory role of PPARγ.
However, 5-aminosalicylic acid (5-ASA) is an anti-
inflammatory drug widely used in the treatment of IBD. It
has been reported that 5-ASA could bind to and activate
PPARγ [92]. Binding of 5-ASA to PPARγ receptor was
found to be similar to the crystal orientation of the TZD
head group of rosiglitazone. These observations indicated
that 5-ASA exerted its anti-inflammatory effect through
activating PPARγ pathway. Based on these observations,
PPARγ ligands have been considered a group of potentially
useful therapeutic agents for CRC and IBD [93, 94]. In a
clinical trial, rosiglitazone was found to produce clinical and
endoscopic remission of patients with ulcerative colitis in the
majority of patients although this study was limited by its low
number of patients [95].
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Table 1: Some of the clinical trials on the role of PPARγ ligands on CRC.
Authors Drug used Number of patients Combined treatment Tumors Effect
Tepmongkol et al. Rosiglitazone 23 Radioiodine Thyroid carcinoma Responded
Hau et al. Pioglitazone 14 Capecitabine/Temozolomide and Rofecoxib Glioma Partial response
Kebebew et al. Rosiglitazone 10 Radioiodine Thyroid carcinoma Responded
Schwartz et al. LY293111 38 No Solid tumors No response
Baetz et al. Ly293111 28 Irinotecan Solid tumors No response
Demetri et al. Troglitazone 3 No Liposarcoma Responded
Smith et al. Rosiglitazone 106 No Prostate carcinoma No response
Tenenbaum et al. Bezafibrate 3011 No Colon cancer Responded
Read et al. Rosiglitazone 23 Bexarotene Solid tumor No response
Debrock et al. Rosiglitazone 12 Pretreatment Liposarcoma negative
Burstein et al. Troglitazone 22 Prechemotherapy or Prehormonal Breast cancer No response
Kulke et al. Troglitazone 25 No Colon cancer No response
Mueller et al. Troglitazone 41 Preandrogen deprivation Prostate cancer No response
Nonsteroidal anti-inflammatory drugs (NSAIDs) are also
a group of PPARγ activators. These agents are a widely used
as anti-inflammatory drugs and pain killers. These agents
can inhibit cyclooxygenase (COX) enzymes [96], and have
a chemopreventive effect in various cancers, including CRC
and gastric cancer [97, 98]. It has been reported that the
chemopreventive effect of NSAIDs in gastrointestinal cancers
was mechanistically attributable to their ability to activate
PPARγ.
It is now widely accepted that activation of PPARγ
may be an important mechanism responsible for the anti-
inflammatory, and anticancer effects of most, if not all
Cox inhibitors. For example, Curcumin, a widely recognized
dietary agent with a strong ability to inhibit NF-κB and
COX-2, was found to activate the PPARγ pathway in colon
cancer [99]. Other COX-2 inhibitors such as indomethacin
and sulindac sulphide also were shown to activate PPARγ
pathways [100]. In addition, inhibition of Cox-2 and acti-
vation of PPARγ may have synergistic effect in inhibiting the
growth of certain cancers such as pancreatic cancer [101].
The mechanisms by which COX inhibition leads to
PPARγ activation are not clearly defined, but may be possibly
due to antagonizing NF-κB activity, suppressing IL-8 and
iNOS expressions, or increased production of prostaglandins
derivertives such as 15d-PGJ2 [102, 103].
Overall, those data suggested that activation of
PPARγ exerts an anticancer effect partially through anti-
inflammatory function.
6. Role of PPARγ in Epithelial Mesenchymal
Transition (EMT) and Tumor Invasion
Metastasis is a subsequent behavior of all malignant tumors,
and often the cause of cancer mortality. EMT plays an impor-
tant role during tumor metastasis. Some of the proteins
involved in EMT could be utilized as potential prognostic
markers or therapeutic targets.
EMT is regulated by multiple signaling pathways [104].
The process starts from ligand-induced activation of tyrosine
kinase receptors. The important ligands that may activate the
tyrosine kinase receptors include epidermal growth factor
(EGF), fibroblast growth factor (FGF), insulin-like growth
factor (ILGF), and hepatocyte growth factor (HGF). Binding
of these ligands to receptors alters the functions of some
of the down-stream target genes: downregulation of the E-
cadherin gene via the transcription factor Snail pathway;
or directly affects cell adhesion and/or the cytoskeletal
dynamics. Notch, Hedgehog, and NF-κB signaling pathways
have also been found to be involved in EMT.
It has been reported that PPARγ promotes EMT by
Rho GTPase-dependent activation of ERK1/2 in intestinal
epithelial cells [105]. RS5444 (a novel third-generation thia-
zolidinedione derivative) caused dramatic changes in cellular
morphology, which were associated with increased motility
and diminished cellular adherence in nontransformed rat
intestinal epithelial cells (RIEs). These data suggest novel
effects of PPARγ on cell-cell and cell-matrix interactions
[49]. However, the precise role and mechanism by which
PPARγ regulates EMT and cancer metastasis are not yet well
defined.
7. Role of PPARγ in Angiogenesis
Angiogenesis plays an important role in the development
and metastasis of all solid cancers. The regulatory role of
PPARγ in angiogenesis has been demonstrated in vitro and
in vivo, as reviewed in details elsewhere [48, 106]. The effect
of PPARγ ligands on angiogenesis is bidirectional, possibly
depends on cell types and specific pathways involved. Most of
the studies showed that PPARγ ligands inhibit angiogenesis,
but opposite results have been reported. For example, 15d-
PGJ2 inhibits angiogenesis via upregulation of HGF, VEGF,
Flt-1 (VEGF receptor-1), and Flk/KDR (VEGF receptor-2).
The same agent may also stimulate angiogenesis via the
induction of heme oxygenase-1 (HO-1), endothelial nitric-
oxide synthase, and hypoxia-inducible factor-1a (HIF-1)
[48]. Large-scale studies will have to be conducted to reveal
the role of PPARγ ligands in angiogenesis in a particular
cancer.
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8. Current Clinical Trials
Althoughmany in vitro and in vivo data have demonstrated a
potential therapeutic role of PPARγ ligands in many cancers,
the results from clinical trials are limited and the efficacy
of PPARγ ligands in most cancers was less satisfactory. The
poor outcome may be partially related to the fact that most
of these clinical trails that turned out to be negative on
therapeutic effect were conducted in patients with refractory
and advanced solid tumors, which are notoriously refractory
to most of the available therapeutic approaches.
Table 1 lists some of the clinical trials on treatment of
different human cancers by PPARγ ligands. From these data,
it is probably more plausible to designate PPARγ ligands as
a group of biological modifier in human cancers rather than
therapeutic agents.
PPARγ agonists are generally well tolerated. The major
adverse effects are gastrointestinal toxicity, include diarrhea,
vomiting, and abdominal pain [44, 45]. Certain TZDs, such
as troglitazone, has been removed from clinical use because
of the severe side effects. Overall, it is still inconclusive
to state a definite therapeutic role of PPARγ agonists in
gastrointestinal cancers.
9. Conclusions
In summary, role of PPARγ in CRC is rather controversial.
PPARγ ligands may exert therapeutic effects on colon cancer
through a PPARγ-dependent and a PPARγ-independent
pathway. The therapeutic effects of the current PPARγ
ligands in colon cancer are less optimal. Thus, new PPARγ
ligands are currently under development. Exploration of
combinational therapy using PPARγ ligands and other
therapeutic drugs should be encouraged.
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